1. Scrip
  2. >>Therapy Areas
  3. >>Blood and Clotting

Fitusiran Delay Dents Sanofi’s Hemophilia Challenge

Company Still Aiming For Universal Therapy

 
• By Andrew McConaghie

New data show fitusiran’s promise across hemophilia A and B, but a switch to a lower dose prompted by safety concerns will delay its filing until 2024.

Sanofi Lyon
A move to target hard-to-treat blood disorders is part of Sanofi's strategy, but has been hit by numerous trial delays. • Source: Alamy

Sanofi retains hopes that fitusiran can play a significant role across all hemophilia patients following the presentation of the Phase III ATLAS studies at the American Society of Hematology (ASH) congress, but it still has much to prove against Roche’s hemophilia A blockbuster, Hemlibra, and late-stage hemophilia B gene therapies.

The two Phase III studies showed fitusiran significantly reduced bleeds in people with hemophilia A or B, with or without inhibitors, which Sanofi hopes could make

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Blood and Clotting

More from Therapy Areas

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.